niacinamide has been researched along with Cutaneous T-Cell Lymphoma in 2 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kießling, MK | 1 |
| Nicolay, JP | 1 |
| Schlör, T | 1 |
| Klemke, CD | 1 |
| Süss, D | 1 |
| Krammer, PH | 1 |
| Gülow, K | 1 |
| Gibson, JF | 1 |
| Foss, F | 1 |
| Cooper, D | 1 |
| Seropian, S | 1 |
| Irizarry, D | 1 |
| Barbarotta, L | 1 |
| Lansigan, F | 1 |
2 other studies available for niacinamide and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; | 2017 |
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm R | 2014 |